Publications
635 results found
Key TJ, Appleby PN, Reeves GK, et al., 2011, Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies, British Journal of Cancer, Vol: 105, Pages: 709-722, ISSN: 1532-1827
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating concentrations of oestrogens andandrogens, but the determinants of these hormones are not well understood.METHODS: Cross-sectional analyses of breast cancer risk factors and circulating hormone concentrations in more than 6000postmenopausal women controls in 13 prospective studies.RESULTS: Concentrations of all hormones were lower in older than younger women, with the largest difference fordehydroepiandrosterone sulphate (DHEAS), whereas sex hormone-binding globulin (SHBG) was higher in the older women.Androgens were lower in women with bilateral ovariectomy than in naturally postmenopausal women, with the largest difference forfree testosterone. All hormones were higher in obese than lean women, with the largest difference for free oestradiol, whereasSHBG was lower in obese women. Smokers of 15 þ cigarettes per day had higher levels of all hormones than non-smokers, with thelargest difference for testosterone. Drinkers of 20 þ g alcohol per day had higher levels of all hormones, but lower SHBG, thannon-drinkers, with the largest difference for DHEAS. Hormone concentrations were not strongly related to age at menarche, parity,age at first full-term pregnancy or family history of breast cancer.CONCLUSION: Sex hormone concentrations were strongly associated with several established or suspected risk factors for breastcancer, and may mediate the effects of these factors on breast cancer risk.
Moore SC, Gunter MJ, Daniel CR, et al., 2011, Common Genetic Variants and Central Adiposity Among Asian-Indians., Obesity
Recent studies have identified common genetic variants that are unequivocally associated with central adiposity, BMI, and/or fasting plasma glucose among individuals of European descent. Our objective was to evaluate these associations in a population of Asian-Indians. We examined 16 single-nucleotide polymorphisms (SNPs) from loci previously linked to waist circumference, BMI, or fasting glucose in 1,129 Asian-Indians from New Delhi and Trivandrum. Trained medical staff measured waist circumference, height, and weight. Fasting plasma glucose was measured from collected blood specimens. Genotype-phenotype associations were evaluated using linear regression, with adjustments for age, gender, religion, and study region. For gene-environment interaction tests, total physical activity (PA) during the past 7 days was assessed by the International Physical Activity Questionnaire (IPAQ). The T allele at the FTO rs3751812 locus was associated with increased waist circumference (per allele effect of +1.58 cm, P(trend) = 0.0015) after Bonferroni adjustment for multiple testing (P(adj) = 0.04). We also found a nominally statistically significant FTO-PA interaction (P(interaction) = 0.008). Among participants with <81 metabolic equivalent (MET)-h/wk of PA, the rs3751812 variant was associated with increased waist size (+2.68 cm; 95% confidence interval (CI) = 1.24, 4.12), but not among those with 212+ MET-h/wk (-1.79 cm; 95% CI = -4.17, 0.58). No other variant had statistically significant associations, although statistical power was modest. In conclusion, we confirmed that an FTO variant associated with central adiposity in European populations is associated with central adiposity among Asian-Indians and corroborated prior reports indicating that high PA attenuates FTO-related genetic susceptibility to adiposity.
Shires DA, Divine G, Schum M, et al., 2011, Colorectal Cancer Screening Use Among Insured Primary Care Patients, AMERICAN JOURNAL OF MANAGED CARE, Vol: 17, Pages: 480-488, ISSN: 1088-0224
- Author Web Link
- Cite
- Citations: 16
Chlebowski RT, McTiernan A, Aragaki AK, et al., 2011, Metformin and breast cancer incidence in postmenopausal diabetic women in the Women's Health Initiative (WHI)., JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 10
Wang T, Rohan TE, Gunter MJ, et al., 2011, A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers, Cancer Epidemiology Biomarkers and Prevention, Vol: 5, Pages: 971-977
BACKGROUND:It is hypothesized that inflammation may mediate the relationship between obesity and endometrial cancer risk. We examined the associations of three inflammation markers, C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α, with risk of endometrial cancer.METHODS:A case-cohort study was nested within the Women's Health Initiative, a cohort of postmenopausal women. Baseline plasma samples of 151 incident endometrial cancer cases and 301 subcohort subjects not using hormones were assayed.RESULTS:CRP, but not IL-6 or TNF-α, was positively associated with endometrial cancer risk after adjusting for age and BMI [HR comparing extreme quartiles (HR q(4)-q(1)) = 2.29; 95% CI = 1.13-4.65; P(trend) = 0.012). After additional adjustment for estradiol and insulin, this association was attenuated (HRq(4)-q(1) = 1.70; 95% CI = 0.78-3.68; P(trend) = 0.127). Obesity (BMI ≥ 30 kg/m(2)) was associated with endometrial cancer risk in an age-adjusted model. The obesity effect was reduced by 48%, 67%, and 77% when either estradiol, CRP, or insulin, respectively, was included in the model, and it became null when all three factors were adjusted for simultaneously.CONCLUSIONS:The association between inflammation, as indicated by a relatively high level of CRP, and endometrial cancer risk may partially be explained by hyperinsulinemia and elevated estradiol. Nevertheless, all three factors contribute to and mediate the link between obesity and endometrial cancer in postmenopausal women not using hormones.IMPACT:The association between obesity and endometrial cancer risk in postmenopausal women may be attributed to inflammation, insulin resistance, and elevated estrogen.
Zervoudakis A, Strickler HD, Park Y, et al., 2011, Reproductive history and risk of colorectal cancer in postmenopausal women, Journal of the National Cancer Institute, Pages: 826-834
BACKGROUND:There are conflicting data regarding the role of sex hormones in colorectal cancer development. Whereas clinical trials data indicate that hormone therapy use reduces the risk of colorectal cancer, data from prospective cohort studies suggest that circulating estrogen levels are positively associated with colorectal cancer risk. A surrogate measure of lifetime estrogen exposure is reproductive history. We investigated the relationship between reproductive factors and the risk of colorectal cancer.METHODS:Subjects were postmenopausal women enrolled in the National Institutes of Health-American Association of Retired Persons Diet and Health Study, a cohort of 214,162 individuals (aged 50-71 years) that included 2014 incident cases of colorectal cancer that occurred over a mean follow-up of 8.2 years. Questionnaires were used to collect data on reproductive factors, including ages at menarche, birth of first child, and menopause; parity, and use of oral contraceptives. Multivariable Cox proportional hazards models were constructed to examine associations between these reproductive factors and the risk of colorectal cancer, with adjustment for established colorectal cancer risk factors. All statistical tests were two-sided.RESULTS:Age at menopause (≥ 55 vs < 40 years: hazard ratio [HR] = 1.50, 95% confidence interval [CI] = 1.23 to 1.83; P(trend) = .008) and age at birth of first child (≥ 30 vs ≤ 19 years: HR = 1.26, 95% CI = 1.01 to 1.58; P(trend) = .05) were positively associated with the risk of colorectal cancer. Among women with no history of hormone therapy use, age at menarche (≥ 15 vs 11-12 years: HR = 0.73, 95% CI = 0.57 to 0.94; P(trend) = .02) and parity (≥ 5 children vs no children: HR = 0.80, 95% CI = 0.63 to 1.02; P(trend) = .10) were inversely associated with the risk of colorectal cancer.CONCLUSION:These data support a role for sex hormones in colorectal tumorigenesis and suggest that greater endogenous estrogen exposure may
Wang T, Rohan TE, Gunter MJ, et al., 2011, A Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal Hormone Nonusers, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Vol: 20, Pages: 971-977, ISSN: 1055-9965
- Author Web Link
- Cite
- Citations: 79
Lin JH, Manson JE, Kraft P, et al., 2011, Estrogen and progesterone-related gene variants and colorectal cancer risk in women, BMC Medical Genetics
BACKGROUND:Observational studies and randomized trials have suggested that estrogens and/or progesterone may lower the risk for colorectal cancer. Inherited variation in the sex-hormone genes may be one mechanism by which sex hormones affect colorectal cancer, although data are limited.METHOD:We conducted a comprehensive evaluation of single nucleotide polymorphisms (SNPs) in genes encoding 3 hormone receptors (ESR1, ESR2, PGR) and 5 hormone synthesizers (CYP19A1 and CYP17A1, HSD17B1, HSD17B2, HSD17B4) among 427 women with incident colorectal cancer and 871 matched controls who were Caucasians of European ancestry from 93676 postmenopausal women enrolled in the Women's Health Initiative Observational cohort. A total of 242 haplotype-tagging and functional SNPs in the 8 genes were included for analysis. Unconditional logistic regression with adjustment for age and hysterectomy status was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).RESULTS:We observed a weak association between the CYP17A1 rs17724534 SNP and colorectal cancer risk (OR per risk allele (A) = 1.39, 95% CI = 1.09-1.78, corrected p-value = 0.07). In addition, a suggestive interaction between rs17724534 and rs10883782 in 2 discrete LD blocks of CYP17A1 was observed in relation to colorectal cancer (empirical p value = 0.04). Moreover, one haplotype block of CYP19A1 was associated with colorectal cancer (corrected global p value = 0.02), which likely reflected the association with the tagging SNP, rs1902584, in the block.CONCLUSION:Our findings offer some support for a suggestive association of CYP17A1 and CYP19A1 variants with colorectal cancer risk.
Gaudet MM, Falk R, Stevens RD, et al., 2011, Serum metabolic profiles and endometrial cancer, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Gupta D, Gunter MJ, Yang K, et al., 2011, Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 21, Pages: 529-534, ISSN: 1048-891X
- Author Web Link
- Cite
- Citations: 22
Gupta D, Gunter MJ, Yang K, et al., 2011, Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma, International Journal of Gynecological Cancer, Vol: 3, Pages: 529-534
HYPOTHESIS:Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC).METHODS:All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ² tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling.RESULTS:Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r² = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77).CONCLUSIONS:Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.
Gunter MJ, Cross AJ, Huang W-Y, et al., 2011, A Prospective Evaluation of C-reactive Protein Levels and Colorectal Adenoma Development, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Vol: 20, Pages: 537-544, ISSN: 1055-9965
- Author Web Link
- Cite
- Citations: 28
Gunter MJ, Cross AJ, Huang WY, et al., 2011, A prospective evaluation of C-reactive protein levels and colorectal adenoma development, Cancer Epidemiology Biomarkers and Prevention, Vol: 3, Pages: 537-544
BACKGROUND:Inflammation is hypothesized to play a role in colorectal tumorigenesis. Circulating levels of C-reactive protein (CRP), a serologic marker of the inflammatory response, have been positively associated with colorectal cancer development in some studies; however, there are limited data on the relation of CRP with colorectal adenomas, established precursors of colorectal cancer.METHODS:A nested case-control investigation of CRP levels and incident colorectal adenoma was conducted in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a randomized trial of 154,942 individuals designed to test the efficacy of flexible sigmoidoscopy on colorectal cancer mortality when performed once, and then repeated 3 to 5 years later. Serum CRP levels were measured in baseline blood specimens from participants who were free of polyps in the left-sided colorectum at the baseline screening procedure, but who were found at the subsequent screen to have at least one colorectal adenoma (n=356), and in a set of polyp-free, frequency-matched controls (n=396).RESULTS:In a multivariable logistic regression model that included established colorectal adenoma risk factors, a 1-unit increase in log CRP level was associated with a 15% reduction in risk of developing colorectal adenoma (OR=0.85, 95% CI, 0.75-0.98, Ptrend=0.01). This association did not differ according to body size, smoking behavior, gender, use of nonsteroidal antiinflammatory drugs, or adenoma location.CONCLUSIONS:High circulating CRP levels may be protective against colorectal adenoma development.IMPACT:Though at contrast with mechanistic data on inflammation and colorectal tumorigenesis, this finding is not inconsistent with prior results on CRP and colorectal adenoma and warrants further investigation.
Johnson CC, Hayes RB, Schoen RE, et al., 2010, Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial, American Journal of Gastroenterology, Vol: 12, Pages: 2646-2655
OBJECTIVES:Non-steroidal anti-inflammatory drugs (NSAIDs) have been documented in animal and human studies to reduce risk for colorectal cancer and adenomatous polyps, but risk modification for subgroups of the population and effects on hyperplastic polyps have been less studied.METHODS:Data on recent use of two frequently ingested NSAIDs, aspirin and ibuprofen, were collected at baseline from participants aged 55-74 years in the 10 centers of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Participants randomized to the intervention arm of the trial received a flexible sigmoidoscopy during a baseline examination. Follow-up of detected polyps was accomplished outside the Trial setting and relevant records were sought and abstracted. Cases (n=4,017) included subjects with a biopsy-proven polyp in the left side of the colon (descending colon, sigmoid, and rectum) detected as a consequence of PLCO screening; controls (n=38,396) were subjects with no left-sided colon polyp.RESULTS:Regular use of aspirin (≥ 4 times/month) in the past year was inversely associated with hyperplastic polyps (odds ratios (OR)=0.8, 95% confidence interval (CI)=0.7-0.9), adenomatous polyps (OR=0.8, 95% CI=0.8-0.9), and advanced adenomas (OR=0.8, 95% CI=0.7-0.9). As frequency of aspirin use increased, the prevalence of polyps decreased significantly for each histological classification (P for trend ≤ 0.0004). Similar patterns were found for adenomas and ibuprofen. Overall protection was consistent in both the descending colon or sigmoid and the rectum, but more evident in males. In males, the OR for heavy use of combined aspirin and ibuprofen (≥ 2 times/day) was 0.6 (95% CI=0.5-0.8), as opposed to 0.9 (95% CI=0.8-1.1) in females. The protective effects of NSAIDs for females were apparent only among those with body mass index (BMI) <25 (OR=0.8, 95% CI=0.7-1.0 for regular use of NSAIDs; P interaction=0.04). We also found a slightly stronger protection of NSA
Johnson CC, Hayes RB, Schoen RE, et al., 2010, Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, AMERICAN JOURNAL OF GASTROENTEROLOGY, Vol: 105, Pages: 2646-2655, ISSN: 0002-9270
- Author Web Link
- Cite
- Citations: 40
Ferrucci LM, Cross AJ, Gunter MJ, et al., 2010, Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma, Pages: 34-45, ISBN: 9783805594271
- Cite
- Citations: 11
Huang GS, Gunter MJ, Arend RC, et al., 2010, Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma, American Journal of Obstetrics and Gynecology, Vol: 3
OBJECTIVE:We sought to evaluate the expression of G protein-coupled receptor 30 (GPR30) and estrogen receptor (ER)beta in uterine carcinosarcoma (CS).STUDY DESIGN:Immunohistochemistry was performed using antibodies to GPR30, ERbeta, ERalpha, and progesterone receptor (PR). The staining intensity and percentage of positive cells were scored for each tissue section. Expression levels were compared using the Wilcoxon rank sum test. Correlation was evaluated by Spearman rho and logistic regression.RESULTS:Compared with normal endometrium, CS had lower ERalpha and PR expression (both P < .01) but higher GPR30 epithelial expression (P = .03). Advanced-stage CS had higher GPR30 (P < .01) and ERbeta (P = .02) epithelial expression compared with early-stage CS. Expression of GPR30 and ERbeta correlated with each other (P < .01), and not with ERalpha or PR.CONCLUSION:In uterine CS, GPR30 and ERbeta are coordinately overexpressed and expression levels increase in advanced-stage disease, supporting the involvement of alternative ERs in disease progression.
Huang GS, Gunter MJ, Arend RC, et al., 2010, Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, Vol: 203, ISSN: 0002-9378
- Author Web Link
- Cite
- Citations: 34
Endogenous Hormones and Breast Cancer Collaborative Group, 2010, Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies, Lancet Oncology, Vol: 6, Pages: 530-542
BACKGROUND:Insulin-like growth factor 1 (IGF1) stimulates mitosis and inhibits apoptosis. Some published results have shown an association between circulating IGF1 and breast-cancer risk, but it has been unclear whether this relationship is consistent or whether it is modified by IGF binding protein 3 (IGFBP3), menopausal status, oestrogen receptor status or other factors. The relationship of IGF1 (and IGFBP3) with breast-cancer risk factors is also unclear. The Endogenous Hormones and Breast Cancer Collaborative Group was established to analyse pooled individual data from prospective studies to increase the precision of the estimated associations of endogenous hormones with breast-cancer risk.METHODS:Individual data on prediagnostic IGF1 and IGFBP3 concentrations were obtained from 17 prospective studies in 12 countries. The associations of IGF1 with risk factors for breast cancer in controls were examined by calculating geometric mean concentrations in categories of these factors. The odds ratios (ORs) with 95% CIs of breast cancer associated with increasing IGF1 concentrations were estimated by conditional logistic regression in 4790 cases and 9428 matched controls, with stratification by study, age at baseline, and date of baseline. All statistical tests were two-sided, and a p value of less than 0.05 was considered significant.FINDINGS:IGF1 concentrations, adjusted for age, were positively associated with height and age at first pregnancy, inversely associated with age at menarche and years since menopause, and were higher in moderately overweight women and moderate alcohol consumers than in other women. The OR for breast cancer for women in the highest versus the lowest fifth of IGF1 concentration was 1.28 (95% CI 1.14-1.44; p<0.0001). This association was not altered by adjusting for IGFBP3, and did not vary significantly by menopausal status at blood collection. The ORs for a difference in IGF1 concentration between the highest and lowest fifth were 1.38
Key TJ, Appleby PN, Reeves GK, et al., 2010, Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies, LANCET ONCOLOGY, Vol: 11, Pages: 530-542, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 470
Zervoudakis A, Schatzkin A, Strickler HD, et al., 2010, Reproductive history and risk of colorectal cancer in postmenopausal women, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, ISSN: 0732-183X
Gunter MJ, 2010, Re: coffee drinking and risk of endometrial cancer-a population-based cohort study, INTERNATIONAL JOURNAL OF CANCER, Vol: 126, Pages: 1770-1770, ISSN: 0020-7136
- Author Web Link
- Cite
- Citations: 1
Gunter MJ, 2010, Re: coffee drinking and risk of endometrial cancer--a population-based cohort study, International Journal of Cancer, Vol: 7
Ferucci LM, Cross AJ, Gunter MJ, et al., 2010, Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma, Journal of Nutrigenetics and Nutrigenomics, Vol: 4, Pages: 170-181
Ferrucci LM, Cross AJ, Gunter MJ, et al., 2010, Xenobiotic Metabolizing Genes, Meat-Related Exposures, and Risk of Advanced Colorectal Adenoma, JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS, Vol: 3, Pages: 170-181, ISSN: 1661-6499
- Author Web Link
- Cite
- Citations: 1
Ferrucci LM, Cross AJ, Gunter MJ, et al., 2010, Xenobiotic Metabolizing Genes, Meat-Related Exposures, and Risk of Advanced Colorectal Adenoma, PERSONALIZED NUTRITION: TRANSLATING NUTRIGENETIC/NUTRIGENOMIC RESEARCH INTO DIETARY GUIDELINES, Vol: 101, Pages: 34-45, ISSN: 0084-2230
- Author Web Link
- Cite
- Citations: 10
Kabat GC, Kim M, Caan BJ, et al., 2009, Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer, INTERNATIONAL JOURNAL OF CANCER, Vol: 125, Pages: 2704-2710, ISSN: 0020-7136
- Author Web Link
- Cite
- Citations: 118
Kabat GC, Kim M, Caan BJ, et al., 2009, Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer, International Journal of Cancer, Vol: 11, Pages: 2704-2710
Experimental and epidemiological evidence suggests that circulating glucose and insulin may play a role in breast carcinogenesis. However, few cohort studies have examined breast cancer risk in association with glucose and insulin levels, and studies to date have had only baseline measurements of exposure. We conducted a longitudinal study of postmenopausal breast cancer risk using the 6% random sample of women in the Women's Health Initiative clinical trials whose fasting blood samples, provided at baseline and at years 1, 3 and 6, were analyzed for glucose and insulin. In addition, a 1% sample of women in the observational study, who had glucose and insulin measured in fasting blood samples drawn at baseline and in year 3, were included in the analysis. We used Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the association of baseline and follow-up measurements of serum glucose and insulin with breast cancer risk. All statistical tests were 2-sided. Among 5,450 women with baseline serum glucose and insulin values, 190 incident cases of breast cancer were ascertained over a median of 8.0 years of follow-up. The highest tertile of baseline insulin, relative to the lowest, was associated with a 2-fold increase in risk in the total population (multivariable hazard ratio 2.22, 95% confidence interval 1.39-3.53) and with a 3-fold increase in risk in women who were not enrolled in the intervention arm of any clinical trial (multivariable hazard ratio 3.15, 95% confidence interval 1.61-6.17). Glucose levels showed no association with risk. Analysis of the repeated measurements supported the results of the baseline analysis. These data suggest that elevated serum insulin levels may be a risk factor for postmenopausal breast cancer.
Gunter MJ, Roh TE, Strickler HD, 2009, Response: Re: Insulin, Insulin-like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women, JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol: 101, Pages: 1031-1032, ISSN: 0027-8874
Rajpathak SN, Wylie-Rosett J, Gunter MJ, et al., 2009, Biomarkers of body iron stores and risk of developing type 2 diabetes, Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, Vol: 5, Pages: 472-479
AIM:Iron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM.METHODS:This nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose.RESULTS:Compared with controls, cases had higher sTfR levels (3.50 +/- 0.07 vs. 3.30 +/- 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95% confidence intervals (95% CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008).CONCLUSIONS:Modestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.